Please assess the completion status of the following clinical trial:

Trial Title: EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Male or female patient, age \>= 18 years at screening. For Japan only: Age \>=20 years at screening~* Patients with chronic HF (Chronic Heart Failure) NYHA (New York Heart Association classification) class II-IV and preserved EF (Ejection Fraction)(LVEF (Left Ventricular Ejection Fraction) \> 40 %) and elevated NT-proBNP (N-terminal of the prohormone brain natriuretic peptide) \> 300 pg/ml for patients without AF, OR \> 900 pg/ml for patients with AF, analysed at the Central laboratory at Visit 1~* Structural heart disease within 6 months prior to Visit 1, OR documented HHF (Hospitalisation for Heart Failure) within 12 months prior to Visit 1~* Stable dose of oral diuretics, if prescribed~* Signed and dated written ICF (informed consent form)~* Further inclusion criteria apply~Exclusion criteria:~* Myocardial infarction, coronary artery bypass graft surgery or other major cardiovascular surgery, stroke or TIA (Transient Ischaemic Attack) in past 90 days prior to Visit 1~* Heart transplant recipient or listed for heart transplant~* Acute decompensated HF (Heart Failure)~* Systolic blood pressure (SBP) \>= 180 mmHg at Visit 2.~* Symptomatic hypotension and/or a SBP \< 100 mmHg~* Indication of liver disease,~* Impaired renal function, defined as eGFR (Estimated Glomerular Filtration Rate) \< 20 mL/min/1.73 m2 (CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration Equation))cr or requiring dialysis~* History of ketoacidosis~* Current use or prior use of a SGLT (Sodium-glucose co-transporter) -2 inhibitor or combined SGLT-1 and 2 inhibitor~* Currently enrolled in another investigational device or drug trial~* Known allergy or hypersensitivity to empagliflozin or other SGLT-2 inhibitors~* Women who are pregnant, nursing, or who plan to become pregnant while in the trial~* Further exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 10 mg Empagliflozin (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).